ARISTOCORT
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARISTOCORT is an injectable small-molecule corticosteroid approved in 1961 for systemic and localized inflammatory and autoimmune conditions. The drug works by binding glucocorticoid receptors to suppress immune response and reduce inflammation. It is administered via injection for conditions requiring rapid or localized anti-inflammatory effect.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating defensive commercial strategy and smaller team focus on market maintenance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARISTOCORT offers limited career growth opportunities due to zero linked job openings and approaching loss of exclusivity. Roles available are primarily defensive and focused on market maintenance rather than product expansion or launch activities.
Brand ManagerField Sales Representative
Worked on ARISTOCORT at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.